Trial · NCT05239624
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
NCT05239624, Phase 2, Active not recruiting, Memorial Sloan Kettering Cancer Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer. Trials, record NCT05239624. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05239624
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
- NCT number
- NCT05239624
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 27 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Urothelial Carcinoma
- Interventions
- Enfortumab vedotin, Pembrolizumab
- First posted
- 2022-02-15
- Last updated
- 2026-10-13
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathologic complete response rate (pCR Rate) | 2 years | Defined as lack of muscle invasive carcinoma (\<pT2) and the absence of lymph node metastasis (N0) in the final cystectomy specimen. Pathologic complete response to perioperative treatment is defined as the absence of carcinoma (pT0) and the absence of lymph node metastases (N0). Pathologists will assess surgical specimens systematically using criteria agreed upon for all conventional neoadjuvant treatment based on the AJCC TNM staging system. |
| Secondary | Event free survival (EFS) | 2 years | Event-free survival will be measured from the initiation of treatment. Any of the following events will qualify as an event: * Primary progression of disease (from time of confirmatory scan) * Recurrence of disease post-operatively with metastatic or local pelvic recurrence after radical cystectomy. * Patients who do not proceed to cystectomy due to toxicity * The assessment of disease recurrence versus development of a second primary tumor will be left to the discretion of the treating physician. If the patient did not progress nor die, the patient will be censored on the date of last follow-up |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05239624
GET https://conductscience.org/api/trials/v1/NCT05239624/registered